Patent: 9,994,615
✉ Email this page to a colleague
Summary for Patent: 9,994,615
Title: | Self-regulated peptide hydrogel for insulin delivery |
Abstract: | A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients\' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia. |
Inventor(s): | Langer; Robert S. (Newton, MA), Anderson; Daniel G. (Sudbiry, MA), Gu; Zhen (Cambridge, MA), Aimetti; Alex Arthur (Waltham, MA) |
Assignee: | Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) |
Application Number: | 14/379,477 |
Patent Claims: | see list of patent claims |
Details for Patent 9,994,615
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 06/14/1996 | ⤷ Try a Trial | 2032-02-17 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 08/06/1998 | ⤷ Try a Trial | 2032-02-17 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 09/06/2007 | ⤷ Try a Trial | 2032-02-17 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 06/06/2017 | ⤷ Try a Trial | 2032-02-17 |
Eli Lilly And Company | HUMALOG | insulin lispro | Injection | 020563 | 11/15/2019 | ⤷ Try a Trial | 2032-02-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |